New Pyridin-3-ylmethyl Carbamodithioic Esters Activate Pyruvate Kinase M2 and Potential Anticancer Lead Compounds.

Yu Zhang,Bin Liu,Xingyu Wu,Ridong Li,Xianling Ning,Yu Liu,Zhenming Liu,Zemei Ge,Runtao Li,Yuxin Yin
DOI: https://doi.org/10.1016/j.bmc.2015.05.041
IF: 3.461
2015-01-01
Bioorganic & Medicinal Chemistry
Abstract:Pyruvate kinase M2 (PKM2) is a key protein responsible for cancer’s Warburg effect. Activation of PKM2 may alter aberrant metabolism in cancer cells, which suggests PKM2 as a tumor selective therapeutic target. In this paper, the lead compound 8 was first discovered as a new kind of PKM2 activator from a random screening of an in-house compound library. Then, a series of lead compound 8 analogs were designed, synthesized and evaluated for their activation of PKM2 and anticancer activities. 7-Azaindole analog 32 was identified as the most potent PKM2 activator. Compounds with potent enzyme activity also exhibited selective anti-proliferation activity on cancer cell lines HCT116, Hela and H1299 compared with non-tumor cell line BEAS-2B. The structure–activity relationships of these compounds were supported by molecular docking results. Preliminary pharmacological studies also showed that compound 32 arrests the cell cycle at the G2/M phase in HCT116 cell line.
What problem does this paper attempt to address?